CVT-3146 is primarily used in research settings as a selective antagonist for the adenosine A2A receptor. This makes it valuable in studying the role of adenosine signaling in various physiological and pathological processes. It is particularly useful in neuroscience research to investigate the receptor's involvement in regulating neurotransmitter release, neuroprotection, and motor control. Additionally, CVT-3146 has been explored in cardiovascular studies to understand its effects on vasodilation and blood flow regulation. Its application extends to potential therapeutic research, including conditions like Parkinson's disease, where adenosine A2A receptor modulation may offer benefits.